Pharmacokinetics of metioprim in normal subjects and patients with impaired renal function | Zendy

H Vergin | Zendy; G B Bishop-Freudling | Zendy; Walter C. Kaiser | Zendy; Marianne Køhler | Zendy; K Strobel | Zendy; F Reutter | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacokinetics of metioprim in normal subjects and patients with impaired renal function

Author(s) -

H Vergin,

G B Bishop-Freudling,

Walter C. Kaiser,

Marianne Køhler,

K Strobel,

F Reutter

Publication year - 1983

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.24.2.190

Subject(s) - pharmacokinetics , impaired renal function , renal function , elimination rate constant , medicine , creatinine , oral administration , pharmacology , endocrinology , urology , volume of distribution

The pharmacokinetics of metioprim, a new competitive inhibitor of bacterial dihydrofolate reductases, were studied after a single oral dose of 100 mg in two young healthy subjects, four elderly volunteers, and eight patients with impaired renal function. The pharmacokinetic parameters of unchanged metioprim were derived by analyzing plasma level curves using a two-compartment model. Plasma half-lives determined for the beta phase were 10.5 to 11.5 h in young volunteers, 12.0 to 12.9 h in elderly subjects, and 13.2 to 15.3 h in patients with renal impairment. A significant correlation between the overall elimination rate constant and the creatinine clearance was demonstrated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research